About the Program

Despite a wealth of antipsychotic treatment options in Canada, many important gaps persist in the management of both bipolar I disorder (BPI) and schizophrenia (SZ).

Please join your peers for an informative and interactive session focusing on the addition of a new agent to the antipsychotic armamentarium.

At the conclusion of the session, participants will be able to:

• Identify current unmet needs for patients with bipolar I disorder (BPI) and schizophrenia (SZ)
• Explain similarities, differences, and potential clinical implications of cariprazine’s pharmacologic characteristics relative to previously approved 2nd and 3rd-generation antipsychotics.
• Describe the efficacy and safety of cariprazine in clinical trials in bipolar I disorder (BPI) and schizophrenia (SZ)
• Define the place of cariprazine in clinical practice among patients with bipolar I disorder (BPI) and schizophrenia (SZ)

Speaker

Dr. Rory Sellmer, MD, FRCPC
Clinical Associate Professor & Residency Program Director, University of Calgary

Location

Ruth’s Chris Steakhouse
115 – 9th Avenue SE,
2nd Floor at the Calgary Tower
FREE PARKING in the attached West Palliser Parkade

RSVP To

Jamie Shewchuk
Jamie.shewchuk@abbvie.com
403-561-0322

Deadline Monday, February 27th, 2023